期刊
ISRAEL MEDICAL ASSOCIATION JOURNAL
卷 16, 期 7, 页码 439-443出版社
ISRAEL MEDICAL ASSOC JOURNAL
关键词
lactate dehydrogenase (LDH); cancer; internal medicine
Background: Serum lactate dehydrogenase (LDH) is elevated in various diseases. Objectives: To analyze serum LDH as a distinguishing clincal biomarker and as a predictor of in-hospital outcome in admitted medical patients, Methods: We analyzed a cohort of all 158 patients with very high isolated LDH (LDH 800 without Concomitant elevations of alanine aminotransferase and aspartate aminotransferase) admitted to our internal medicine department during a 3 year period. Epidemiologic and clinical data, as well as the final diagnosis and Outcome were recorded and compared with those of a cohort of all 188 consecutive control:patients. Results: Very high isolated LDH was a distinguishing biomarker for the presence of cancer (27% vs. 4% in the LDH group and controls respectively, P<0.0001), liver metastases (14% vs. 3%, P<0.0001), hematologic malignancies (5% vs. 0%, P=0.00019), and infection (57% vs. 28%, P<0.0001). Very high isolated LDH was a marker for severe prognosis, associated with more admission days (9.3 vs. 4.1, P<0.0001), significantly more in-hospital major complications, and high mortality rate (26.6% vs. 4.3%, P<0.0001). Finally, very high isolated LDH was found in a multivariate regression analysis to be an independent predictor of mortality. Conclusions: The presence Of very high isolated LDH warrants thorough investigation for the presence of severe underlying disease, mostly Metastatic cancer, hematologic malignancies, and infection. Moreover, it is a marker for major in-hospital complications and is an independent predictor of mortality in admitted medical patients,
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据